ArticleFuture oncology (London, England)2024

Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial.

Saaya Tsutsué et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.